Banco Santander S.A. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Banco Santander S.A. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,698 shares of the biopharmaceutical company’s stock after buying an additional 127 shares during the quarter. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $8,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Swedbank AB purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $129,257,000. Epoch Investment Partners Inc. acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.3 %

Regeneron Pharmaceuticals stock opened at $745.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a market capitalization of $81.92 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 2.81 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50 day simple moving average of $953.38 and a 200-day simple moving average of $1,028.16.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Citigroup began coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.